INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Volume 11, Number 7 • July 1990

The Official Journal of The Society of Hospital Epidemiologists of America

From SmithKline Biologicals/
Smith Kline &French Laboratories

Engerix-B®

Hepatitis B Vaccine (Recombinant)

0, 1, 2 Month Dosing Regimen for Certain Populations*

20 mcg recombinant dose helps to ensure immune response in adult patients of all ages

Choice of dosing regimens

Adult dose (mcg)
Standard dosing regimen (0, 1 and 6 months)
New 0, 1, 2 month dosing regimen for certain populations*
Published efficacy data: Neonates born of infected mothers'
VACTRAC™—computer software for vaccination tracking and compliance
Bar-coded, unit-dose vials
Lowest cost per dose[2]

*For those recently exposed to the virus (including needlestick exposure), certain travelers to high-risk areas, and neonates born of infected mothers. When prolonged maintenance of protective antibody titers is desired, a booster dose at month 12 is recommended.

†Hepatitis B Vaccine (Recombinant), MSD.

‡Please see brief summary of prescribing information on adjacent page for a complete listing of adverse reactions, contraindications, warnings and precautions.

Lowest Cost Per Dose[2]

Extensively Tested and Well Tolerated‡

State-of-the-art recombinant technology

14 million doses distributed in over 87 countries[3]

Switch to 'Engerix-B'

Can be used to complete a course of vaccination initiated with another hepatitis B vaccine[3,4]

Engerix-B®	Recombivax HB®†
20	10
Yes	Yes
Yes	No
Yes	Yes
Yes	No
Yes	No
Yes	No



Manufactured by
SmithKline Biologicals
Rixensart, Belgium

Distributed by
Smith Kline & French Laboratories
Philadelphia, PA 19101

Engerix-B®

Hepatitis B Vaccine (Recombinant)

See complete prescribing information in **SK&F literature** or ***PDR*. The following is a brief summary.**

INDICATIONS AND USAGE: 'Engerix-B' is *indicated for immunization* against infection caused by all known subtypes of hepatitis B virus Immunization is recommended in persons of all ages, especially those who are or will be, al increased risk of exposure to hepatitis El virus

CONTRAINDICATIONS: Hypersensitivity to yeast or any other component of the vaccine is a contraindication for use of the vaccine

WARNINGS: Do not give additional injections t o patients experiencing hypersensitivity alter an 'Engerix-B' injection. (See CONTRAINDICATIONS.)

Hepatitis B has a long incubation period Hepatitis B vaccination may not *prevent hepatitis B infection in individuals* who had a* unrecognized hepatitis B infection at the time of vaccine administration Additionally, it may not prevent infection in individuals who do not achieve protective antibody titers

PRECAUTIONS: **General:** As with any percutaneous vaccme, keep epinephrine available for use in case of anaphylaxis or anaphylactoid reaction.

As with any vaccme, delay administration, if possible, in persons with any febrile illness or active infection.

Pregnancy: Pregnancy Category C Animal reproduction studies have not been conducted with 'Engerix-B' It is also not known whether 'Engerix-B' can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity Give 'Engenx B' to a pregnant woman only if clearly needed

Nursing Mothers: It is not known whether 'Engerix-B' is excreted in human milk Because many drugs are excreted in human milk, use caution when giving 'Engerix-B' to a nursing woman

Pediatric Use: 'Engerix-B' has been shown to be well tolerated and highly immunogenic in infants and children of all ages Newborns also respond well. maternally transferred antibodies do not interfere with the active immune response to the vaccme

ADVERSE REACTIONS: 'Engerix-B' is generally well tolerated During clinical studies involving over 10,000 individuals distributed over all age groups, no serious adverse reactions attributable to vaccine administration were reported As with any vaccme, however, it is possible that expanded commercial use of the vaccine could weal rare adverse reactions not observed in clinical studies

Ten double-blind studies involving 2,252 subjects showed no significant difference in the frequency or severity of adverse experiences between 'Engerix-B' and plasma-dewed vaccines In 36 clinical studies a total of 13,495 doses of 'Engerix B' were administered to 5,071 healthy adults and children who were initially seronegative for hepatitis B markers! and healthy neonates. All subjects were monitored for 4 days post-administration Frequency of adverse *experiences* tended to decrease with successive doses of 'Engerix-B' Using a symptom checklist,* the most frequently reported adverse reactions were injection site soreness (22%). and fatigue* (14%) Other reactions are listed below

Incidence 1% to 10% of Injections: Induration; erythema; swelling, fever (> 37.5%): headache', dizziness *

'Parent or guardian completed forms for children and neonates Neonatal checklist did not include headache, fatigue or dizziness

Incidence < 1% of Injections: P a m ; pruritus; ecchymosis; sweating; malaise; chills; weakness, flushmg, tingling: hypotension; influenza-like symptoms; *upper respiratory* tract *illnesses*: nausea. *anorexia*; *abdominal pain*/ cramps; vomiting; constipation. diarrhea; lymphadenopathy; pain/stiffness in arm, shoulder or neck. arthralgia; myalgia; back pain; rash, urticaria; petechiae; erythema; somnolence. insomnia; irritability; agitation

Additional adverse experiences have been reported with the commercial use of 'Engerix-B' outside the United States Those listed below are to serve as alerting information to physicians: Anaphylaxis; erythema multiforme includm g Stevens-Johnson syndrome; angioedema; arthritis; tachycardial/palpitations; bronchospasm including asthma-like symptoms, abnormal liver function tests, migraine; syncope; paresis; neuropathy Including hypoesthesia, paresthesia, Guillain-Barré syndrome and Bell's patsy, transverse myelitis; *thrombocytopenia*; eczema; *purpura*; herpes *zoster*; *vertigo*; *conjunctivitis*; keratitis; visual disturbances

Potential Adverse Experiences In addition, certain other adverse experiences not observed with 'Engerix-B' have been reported with Heptavax-B®† and/or Recombivax HB® ‡ Those listed below are to serve as alerting information to *physicians Optic* neuritis

HOW SUPPLIED: 20 mcg/mL in Single-Dose Vials in packages of 1.10 and 25 vials

NDC 0007-3860-01 (package of 1)
NDC 0007-3860-11 (package of 10)
NDC 0007-3860-16 (package of 25)

10 mcgl0.5 mL in Single-Dose Vials in packages of 1 vial

NDC 0007-3859-01 (package Ot 1)

† *plasma-derived, Hepatitis B Vaccine*, MSD
‡ yeast-dewed. Hepatitis B Vaccine, MSD

Manufactured b **SmithKline Biologicals**, Rixensart, Belgium
Distributed by J m o t h **Kline & French Laboratories**
Division of SmithKline Beckman Corp., Philadelphia, PA 19101

Date of issuance Aug 1939

BAS-EB L6

Engerix-B is a registered trademark of SmithKline Beckman Corporation

References:
1. Poovorawan Y, Sanpavat S, Pongpunlert W, et al: Protective efficacy of a recombinant DNA *hepatitis* B vaccine in neonates *of* HBe *antigen-positive* mothers. *JAMA* 1989; 261(22):3278–3281.
2 Based on Medi-Span* Hospital Formulary Pricing Guide, December 1989. 3. Data on file, SK&F. 4. Bush L, Moonsammy G, Boscia J: Evaluation of initiating a hepatitis B vaccination schedule with one vaccine and completing it with another. *Hepatology* 1989; 10:689.

VOLUME 11, NUMBER 7 JULY 1990

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

The ideas and opinions expressed by contributing authors do not necessarily reflect those of the editors or publisher.

Publisher: Infection Control and Hospital Epidemiology (ISSN-0899-823X) is published monthly by SLACK Incorporated 6900 Grove Road Thorofare New Jersey 08086 Telephone (609) 848-1000

Subscriptions: Requests should be addressed to the publisher (except Japan) I" Japan contact Woodbell Incorporated, 4-22-11, Kitakasai Edogawaku. Tokyo 134. Japan Subscription rates in the US and possessions Individual One year-$60 00. Two years-$95 00 Three years-$125 00 Institutional One year—$70 00 Two years—$110 00. Three years—$150 00. Canada $18 00 additional each year. all other countries $30 00 additional each year Single copies of current issues may be obtained for88 00, United States and possessions; $16 00 all other countries

Change of address: Notice should be sent to the publisher six weeks in advance of effective date Include old and new addresses with zip codes The publisher cannot accept responsibility for undelivered copies Second-class postage is paid at Thorofare. New Jersey 08086, and additional entry points Postmaster: Send address changes to SLACK Incorporated. 6900 Grove Road Thorofare, NJ 08086

As of Volume 1 Number 1 INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY is listed i" Index *Medicus*, Current *Contents—Clinical Practice Hospital Literature index Cumulative Index to Nursing and Allied* Health *Literature* and Nursing *Abstracts*

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY®

EDITORIAL OFFICES
Vanderbilt University School of Medicine
A-1131 Medical Center North
Nashville, TN 37232-2637
(615) 343-1095; (615) 343-1882 (FAX)
Email: iche@mcmail.vanderbilt.edu

EDITOR
Michael D. Decker, MD, MPH

MANAGING EDITOR
Susan Cantrell

STATISTICAL EDITOR
Beverly G. Mellen, PhD

SENIOR ASSOCIATE EDITORS
C. Glen Mayhall, MD
Gina Pugliese, RN, MS
William Schaffner, MD

ASSOCIATE EDITORS
Donald A. Goldmann, MD
Didier Pittet, MD, MS
Andreas Widmer, MD, MS

SECTION EDITORS

Beyond Infection Control: The New Hospital Epidemiology
Bryan P. Simmons, MD
Stephen B. Kritchevsky, PhD
Memphis, Tennessee
Wing Hong Seto, MD
Hong Kong

Disinfection and Sterilization
William A. Rutala, PhD, MPH
Chapel Hill, North Carolina

Emerging Infectious Diseases
Larry J. Strausbaugh, MD
Portland, Oregon
Robert W. Pinner, MD
Atlanta, Georgia

From the Laboratory
Marcus Zervos, MD
Royal Oak, Michigan
Fred C. Tenover, PhD
Atlanta, Georgia

Information Management
John A. Sellick, DO
Buffalo, New York

The International Perspective
Mary D. Nettleman, MD, MS
Richmond, Virginia

Issues in Surgery
James T. Lee, MD, PhD
St. Paul, Minnesota

Medical News
Gina Pugliese, RN, MS
Chicago, Illinois
Martin S. Favero, PhD
Irvine, California

Practical Healthcare Epidemiology
Loreen A. Herwaldt, MD
Iowa City, Iowa

SHEA News
Murray D. Batt, MD
Clarksburg, West Virginia

Statistics for Hospital Epidemiology
David Birnbaum, PhD, MPH
Sidney, British Columbia, Canada

Topics in Long-Term Care
Philip W. Smith, MD
Omaha, Nebraska

Topics in Occupational Medicine
David Weber, MD, MPH
Chapel Hill, North Carolina

SLACK Incorporated
6900 Grove Road
Thorofare, New Jersey 08086
(609) 848-1000

Vice President/Group Publisher
Richard N. Roash

Publisher
John C. Carter

Editorial Director
Jennifer Kilpatrick

Production Editor
Shirley P. Strunk, ELS

Assistant Editor
Eileen C. Anderer

Circulation Manager
Lester J. Robeson, CCCP

Production Director
Christine Malin

Production Coordinator
Joanne Patterson

Publishing Director/ Advertising
Wayne McCourt

Pharmaceutical Group Sales Director
Michael LoPresti

Advertising Sales Representative
Jennine Kane

Classified/Recruitment Sales Manager
Michele Burch

"Synergism..."

Synergism is the working relationship between two ingredients which results in performance superior to that achieved by each ingredient working separately.

Synergism is Sporicidin. Glutaraldehyde combined with an alkaline phenate system produces superior disinfecting properties.* Patented Sporicidin disinfects with substantually less glutaraldehyde than other products.

Synergism makes Sporicidin tuberculocidal in only ten minutes at room temprature, 68° F and above, when diluted 1:16. Other alkaline glutaraldehyde products cannot be diluted and/or require longer contact times with heating to 77°F.

Sporicidin fulfills the CDC definition of high level disinfection using the lowest concentration of glutaraldehyde... because of Synergism.

* *Journal of Clinical Microbiology, November 1985, p. 735 - 739*

Sporicidin INTERNATIONAL

12000 Old Georgetown Road, Rockville, Maryland 20847